2 weeks Ago By ABMN Staff
Y-mAbs Therapeutics, Inc. ( NASDAQ:YMAB – Get Free Report ) COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.
69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares in the company, valued at $449,514.
The sale was disclosed in a document filed with the SEC, which is available through the SEC website . Y-mAbs Therapeutics Stock Performance Y-mAbs Therapeutics stock opened at $14.02 on Friday.
Y-mAbs Therapeutics, Inc. has a fifty-two week low of $4.69 and a fifty-two week high of $20.
90. The company has a market capitalization of $624.87 million, a PE ratio of -28.
61 and a beta of 0.66. The company has a 50 day moving average price of $12.
23 and a 200-day moving average price of $13.76. Y-mAbs Therapeutics ( NASDAQ:YMAB – Get Free Report ) last posted its quarterly earnings results on Monday, August 12th.
The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.
08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.
44%. The firm had revenue of $22.80 million for the quarter, compared to the consensus estimate of $23.
09 million. During the same period in the previous year, the company posted ($0.14) EPS.
On average, analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.57 earnings per share for the current year.
Hedge Funds Weigh In On Y-mAbs Therapeutics Wall Street Analysts Forecast Growth Several brokerages have weighed in on YMAB. Wedbush reissued an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, August 12th.
Canaccord Genuity Group reissued a “buy” rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Cantor Fitzgerald started coverage on Y-mAbs Therapeutics in a report on Friday, August 16th.
They set an “overweight” rating and a $20.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $22.
00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company.
According to MarketBeat, Y-mAbs Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $21.14. Read Our Latest Report on YMAB Y-mAbs Therapeutics Company Profile ( Get Free Report ) Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally.
It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. Further Reading Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
